ALNY logo

Alnylam Pharmaceuticals (ALNY) Current Liabilities

Annual Current Liabilities

$1.19 B
+$218.49 M+22.58%

December 31, 2024

Summary

Performance

1-Year Change

+22.58%

3-Year Change

+70.51%

5-Year Change

+236.44%

15-Year Change

+722.37%

ALNY Current Liabilities Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Sector Rank

93.72%
ALNY annual total current liabilities is higher than 93.72% of companies in Healthcare sector

High & Low

All-time High

$1.19 B
ALNY annual total current liabilities is currently at an all-time high

3-Year Low

$695.71 M
ALNY annual total current liabilities is currently +70.51% above its 3-year low

Earnings dates

Last Annual Earnings Report Date

Dec 31, 2024
ALNY previous annual earnings announcement was published on Dec 31, 2024

Next Annual Earnings Report Date

N/A
ALNY next annual earnings announcement has not yet been scheduled

OtherALNYbalance sheetmetrics:

Annual Total Liabilities

$4.17 B
ALNY annual total liabilities is $4.17 billion

Annual Total Long Term Liabilities

$2.99 B
ALNY annual total long term liabilities is $2.99 billion

Annual Total Assets

$4.24 B
ALNY annual total assets is $4.24 billion

Annual Current Assets

$3.30 B
ALNY annual total current assets is $3.30 billion

Quarterly Current Liabilities

$1.19 B
-$34.39 M-2.82%

December 31, 2024

Summary

Performance

3-Month Change

-2.82%

1-Year Change

+22.58%

3-Year Change

+22.58%

5-Year Change

+22.58%

ALNY Quarterly Current Liabilities Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Sector Rank

93.85%
ALNY quarterly total current liabilities is higher than 93.85% of companies in Healthcare sector

High & Low

All-time High

$1.22 B
ALNY quarterly total current liabilities is currently -2.82% below its historical high of $1.22 billion

3-Year Low

$605.96 M
ALNY quarterly total current liabilities is currently +95.77% above its 3-year low

Earnings dates

Last Quarterly Earnings Report Date

Dec 31, 2024
ALNY previous earnings announcement was published on Dec 31, 2024

Next Quarterly Earnings Report Date

May 2, 2025
ALNY next earnings announcement is scheduled for May 2, 2025

OtherALNYbalance sheetmetrics:

Quarterly Total Liabilities

$4.17 B
ALNY quarterly total liabilities is $4.17 billion

Quarterly Long Term Liabilities

$2.99 B
ALNY quarterly total long term liabilities is $2.99 billion

Quarterly Total Assets

$4.24 B
ALNY quarterly total assets is $4.24 billion

Quarterly Current Assets

$3.30 B
ALNY quarterly total current assets is $3.30 billion

Current Liabilities Formula

Current Liabilities = Accounts Payable + Short-Term Debt + Accrued Expenses + Other Current Liabilities

Annual Current Liabilities

$1.19 B
ALNY annual total current liabilities is $1.19 billion

Annual Accounts Payable

$88.42 M
ALNY annual accounts payable is $88.42 million

Annual Short Term Debt

$41.89 M
ALNY annual short term debt is $41.89 million

ALNY Current Liabilities Trends

PeriodPeriodAnnualAnnualQuarterlyQuarterly
1 y1 year+22.6%+22.6%
3 y3 years+70.5%+22.6%
5 y5 years+236.4%+22.6%

ALNY Current Liabilities Highs & Lows

PeriodPeriodAnnual vs highAnnual vs highAnnual vs lowAnnual vs lowQuarter. vs highQuarter. vs highQuarter. vs lowQuarter. vs low
3 y3-yearat high+70.5%-2.8%+95.8%
5 y5-yearat high+236.4%-2.8%+250.2%
alltimeall timeat high>+9999.0%-2.8%>+9999.0%

Alnylam Pharmaceuticals Current Liabilities History

DateAnnualQuarterly
Dec 2024
$1.19 B(+22.6%)
$1.19 B(-2.8%)
Sep 2024
-
$1.22 B(+15.7%)
Jun 2024
-
$1.06 B(+12.1%)
Mar 2024
-
$941.71 M(-2.7%)
Dec 2023
$967.79 M(+26.0%)
$967.79 M(+1.9%)
Sep 2023
-
$949.78 M(+20.4%)
Jun 2023
-
$788.64 M(+17.1%)
Mar 2023
-
$673.39 M(-12.3%)
Dec 2022
$767.91 M(+10.4%)
$767.91 M(-0.6%)
Sep 2022
-
$772.79 M(+17.5%)
Jun 2022
-
$657.68 M(+8.5%)
Mar 2022
-
$605.96 M(-12.9%)
Dec 2021
$695.71 M(+18.9%)
$695.71 M(+13.9%)
Sep 2021
-
$610.66 M(+10.1%)
Jun 2021
-
$554.65 M(+12.1%)
Mar 2021
-
$494.82 M(-15.5%)
Dec 2020
$585.27 M(+66.0%)
$585.27 M(+21.9%)
Sep 2020
-
$480.24 M(+25.0%)
Jun 2020
-
$384.30 M(+13.4%)
Mar 2020
-
$338.79 M(-3.9%)
Dec 2019
$352.59 M(+96.4%)
$352.59 M(-0.1%)
Sep 2019
-
$352.86 M(+7.4%)
Jun 2019
-
$328.60 M(+120.3%)
Mar 2019
-
$149.16 M(-16.9%)
Dec 2018
$179.49 M(+24.4%)
$179.49 M(+47.7%)
Sep 2018
-
$121.50 M(+6.9%)
Jun 2018
-
$113.66 M(-1.5%)
Mar 2018
-
$115.38 M(-20.0%)
Dec 2017
$144.25 M(+9.5%)
$144.25 M(+42.8%)
Sep 2017
-
$101.05 M(-7.1%)
Jun 2017
-
$108.73 M(+13.5%)
Mar 2017
-
$95.79 M(-27.3%)
Dec 2016
$131.70 M(+112.1%)
$131.70 M(+61.1%)
Sep 2016
-
$81.76 M(+15.8%)
Jun 2016
-
$70.58 M(+6.3%)
Mar 2016
-
$66.37 M(+6.9%)
Dec 2015
$62.10 M(-34.9%)
$62.10 M(+8.7%)
Sep 2015
-
$57.11 M(-14.2%)
Jun 2015
-
$66.60 M(-17.5%)
Mar 2015
-
$80.69 M(-15.4%)
Dec 2014
$95.33 M
$95.33 M(+67.7%)
Sep 2014
-
$56.85 M(+5.8%)
Jun 2014
-
$53.74 M(-35.9%)
DateAnnualQuarterly
Mar 2014
-
$83.83 M(+55.6%)
Dec 2013
$53.86 M(+11.4%)
$53.86 M(-1.9%)
Sep 2013
-
$54.90 M(+3.4%)
Jun 2013
-
$53.07 M(+6.7%)
Mar 2013
-
$49.75 M(+2.9%)
Dec 2012
$48.34 M(-40.3%)
$48.34 M(-11.7%)
Sep 2012
-
$54.76 M(-4.0%)
Jun 2012
-
$57.06 M(-14.4%)
Mar 2012
-
$66.64 M(-17.7%)
Dec 2011
$80.99 M(-20.6%)
$80.99 M(-13.8%)
Sep 2011
-
$93.93 M(-6.6%)
Jun 2011
-
$100.53 M(+1.2%)
Mar 2011
-
$99.34 M(-2.6%)
Dec 2010
$102.05 M(-7.8%)
$102.05 M(+2.6%)
Sep 2010
-
$99.43 M(-2.5%)
Jun 2010
-
$102.03 M(+3.5%)
Mar 2010
-
$98.57 M(-11.0%)
Dec 2009
$110.73 M(+11.3%)
$110.73 M(+9.5%)
Sep 2009
-
$101.12 M(-1.2%)
Jun 2009
-
$102.33 M(-1.8%)
Mar 2009
-
$104.25 M(+4.8%)
Dec 2008
$99.45 M(+19.1%)
$99.45 M(-2.5%)
Sep 2008
-
$102.02 M(-3.5%)
Jun 2008
-
$105.73 M(+24.5%)
Mar 2008
-
$84.91 M(+1.7%)
Dec 2007
$83.48 M(+264.1%)
$83.48 M(-4.5%)
Sep 2007
-
$87.46 M(+222.6%)
Jun 2007
-
$27.11 M(+15.4%)
Mar 2007
-
$23.50 M(+2.5%)
Dec 2006
$22.93 M(+24.0%)
$22.93 M(+6.5%)
Sep 2006
-
$21.53 M(+4.5%)
Jun 2006
-
$20.60 M(+3.1%)
Mar 2006
-
$19.99 M(+8.1%)
Dec 2005
$18.48 M(+181.1%)
$18.48 M(+131.0%)
Sep 2005
-
$8.00 M(-11.3%)
Jun 2005
-
$9.02 M(+47.0%)
Mar 2005
-
$6.14 M(-6.6%)
Dec 2004
$6.58 M(+71.0%)
$6.58 M(-1.0%)
Sep 2004
-
$6.64 M(-23.7%)
Jun 2004
-
$8.70 M(+6.2%)
Mar 2004
-
$8.19 M(+113.1%)
Dec 2003
$3.84 M(+43.8%)
$3.84 M
Dec 2002
$2.67 M
-

FAQ

  • What is Alnylam Pharmaceuticals annual total current liabilities?
  • What is the all time high annual current liabilities for Alnylam Pharmaceuticals?
  • What is Alnylam Pharmaceuticals annual current liabilities year-on-year change?
  • What is Alnylam Pharmaceuticals quarterly total current liabilities?
  • What is the all time high quarterly current liabilities for Alnylam Pharmaceuticals?
  • What is Alnylam Pharmaceuticals quarterly current liabilities year-on-year change?

What is Alnylam Pharmaceuticals annual total current liabilities?

The current annual current liabilities of ALNY is $1.19 B

What is the all time high annual current liabilities for Alnylam Pharmaceuticals?

Alnylam Pharmaceuticals all-time high annual total current liabilities is $1.19 B

What is Alnylam Pharmaceuticals annual current liabilities year-on-year change?

Over the past year, ALNY annual total current liabilities has changed by +$218.49 M (+22.58%)

What is Alnylam Pharmaceuticals quarterly total current liabilities?

The current quarterly current liabilities of ALNY is $1.19 B

What is the all time high quarterly current liabilities for Alnylam Pharmaceuticals?

Alnylam Pharmaceuticals all-time high quarterly total current liabilities is $1.22 B

What is Alnylam Pharmaceuticals quarterly current liabilities year-on-year change?

Over the past year, ALNY quarterly total current liabilities has changed by +$218.49 M (+22.58%)